News

XOMA Royalty Achieves Remarkable Growth in Financial Results

XOMA Royalty Achieves Remarkable Growth in Financial Results

XOMA Royalty's Financial Performance Update

XOMA Royalty Corporation (NASDAQ: XOMA) has recently reported its impressive financial results for the fourth quarter and the full year of 2024, showcasing significant growth and strategic achievements that reflect the company's commitment to enhancing shareholder value.

Key Highlights from 2024

Among the remarkable milestones achieved this year, XOMA has successfully expanded its royalty and milestone portfolio. The company doubled its portfolio to over 120 assets with substantial milestone potential from various strategic transactions.

In a major push to unlock shareholder value, XOMA has completed two whole company acquisitions. Notably, the FDA has approved Day One's OJEMDA™ (tovorafenib) and Zevra's MIPLYFFA™ (arimoclomol), which further strengthens XOMA’s market position.

In the fourth quarter alone, the company reported cash receipts totaling $4 million, contributing to an impressive $46.3 million in cash receipts for the full year 2024. This financial strength positions XOMA well for future growth and investment opportunities.

Royalty and Milestone Acquisitions

XOMA Royalty has made significant strides in acquiring economic interests in high-potential assets. Noteworthy transactions include a $15 million royalty agreement with Twist Bioscience, representing a 50% stake in future revenues from over 60 partnered early-stage programs. Additionally, for a $22 million upfront payment, XOMA added three best- or first-in-category assets from Daré Bioscience to its portfolio, ensuring a robust pipeline of innovative products.

Company Acquisitions Driving Growth

XOMA’s acquisition strategy has proven successful, highlighted by the acquisition of Kinnate Biopharma, which added $7.8 million in cash and five assets to its portfolio. Similarly, the purchase of Pulmokine Inc. has secured a milestone and royalty interest in Gossamer Bio and Chiesi Farmaceutici's seralutinib, demonstrating XOMA’s commitment to investing in growth opportunities within the biotech sector.

Regulatory Approvals and Product Developments

Regulatory achievements for XOMA include the FDA approvals of OJEMDA™ for pediatric low-grade glioma and MIPLYFFA™ for Niemann-Pick disease type C. These approvals not only drive immediate financial opportunities through milestone payments but also reinforce XOMA's strategic focus on therapies addressing significant unmet medical needs.

Financial Metrics and Future Outlook

According to Tom Burns, CFO of XOMA Royalty, the anticipated incoming cash payments from royalties look promising, leading the company to anticipate becoming cash flow positive consistently. In terms of revenues, XOMA recorded total revenue of $28.5 million for the full year, a significant rise from previous years, driven primarily by an increase in income from purchased receivables.

R&D expenses have grown this year due to costs associated with clinical trials for KIN-3248. Still, leadership expects these expenses to normalize in the coming years, correlating with strategic operational efficiencies and growth from acquisitions.

Despite a net loss reported at $13.8 million for the year, this represents an improvement over $40.8 million in losses in 2023, underscoring the positive trajectory the company is on.

Investment in Innovation

XOMA's innovative spirit is evident in its strong pipeline, including 11 Phase 3 assets. The company looks forward to key readouts in 2025 from various leading assets, which could significantly alter their revenue trajectory. With over $100 million in cash on hand, XOMA is strategically poised to continue its focus on sustainable cash flow through its growing royalty and milestone portfolio.

Looking Ahead to 2025

As XOMA moves into 2025, several anticipated events signal exciting opportunities ahead. These include upcoming regulatory filings, further insights from clinical trials, and additional potential approvals, all of which could enhance shareholder value significantly.

XOMA also plans to advance its product development strategy, focusing on partnerships that align with its innovative pipeline. The roadmap for the year ahead illustrates a commitment to both patient outcomes and shareholder interests.

Frequently Asked Questions

What were the key financial results for XOMA in 2024?

XOMA reported a total revenue of $28.5 million for the full year 2024, with significant cash receipts of $46.3 million.

What acquisitions has XOMA made recently?

This year, XOMA acquired Kinnate Biopharma and Pulmokine Inc., expanding its portfolio of assets and enhancing its market position.

Which products received FDA approval?

The FDA approved Day One's OJEMDA™ and Zevra's MIPLYFFA™, strengthening XOMA's portfolio with significant earning potential.

What is XOMA's strategy for growth?

XOMA focuses on acquiring innovative biotech companies and their related assets while expanding its portfolio to drive revenue through royalties and milestones.

What are the expectations for 2025?

XOMA anticipates key trial readouts and regulatory approvals throughout 2025 that will potentially enhance its revenue streams and strengthen its market presence.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Santa Ana Branch Expansion Tests Local Credit Demand

Updated Category News Views 28

A Bigger Room for Smaller Financial Decisions A branch relocation across the same shopping center may sound mundane, but it says plenty about where California Credit Union sees durable demand. The credit union has opened a larger Santa Ana office at 1601 W. 17th Street, Suite C, replacing its prior spot in the same center. This is not some chest-thumping expansion into an...

Continue Reading
Hydron’s Bailey Test Puts RNG Cost Claims to Real Work

Updated Category News Views 15

Landfill gas is messy stuff, which is exactly why Hydron Energy’s Bailey Landfill demonstration in Chilliwack deserves more attention than another clean-energy press release. The British Columbia company is putting its INTRUPTor™ gas-separation system into an operating environment alongside FortisBC and the City of Chilliwack, where the machinery has to deal with real...

Continue Reading
HiTHIUM's 8-Hour Storage Pitch Faces Real Grid Tests

Updated Category News Views 136

Eight hours of stored electricity is where the sales brochure meets the ugly parts of the grid. HiTHIUM arrived at RE+ 2026 in Las Vegas, held November 17 through 19, with a broad storage pitch: systems ranging from two to eight hours, lithium-ion and sodium-ion chemistry, plus the software and validation work needed to make a battery plant behave when the local grid gets...

Continue Reading
Lake Ridge Sets $0.68 Dividend as 2026 Payouts Rise

Updated Category News Views 155

A community bank raising its cash return is not fireworks, but it gets my attention faster than another glossy growth slogan. Lake Ridge Bancorp has declared a fourth-quarter 2026 dividend of $0.68 per share, payable December 16 to shareholders of record on November 30. That is a plain, useful announcement from OTCQX:LRBI, and plain is often underrated when you are...

Continue Reading
Gildan Lawsuit Puts Revenue Controls Under a Harsh Light

Updated Category News Views 36

Receivables have a nasty way of becoming everybody’s problem once the story cracks. Gildan Activewear is staring at that uncomfortable reality after a securities fraud class action was filed on behalf of investors who bought or acquired shares between February 19, 2025 and June 15, 2026. The case, Cortez v. Gildan Activewear Inc., is pending in the U.S. District Court...

Continue Reading
Roof Leaks Demand Diagnosis Before the Repair Bill

Updated Category News Views 95

A brown ring on a ceiling is often the last witness, not the crime scene. That is the useful, unglamorous point in Jonathan Floyd's HelloNation discussion of roof leaks: water has plenty of ways to move after it slips past a roof's defenses. Homeowners understandably stare at the stain and assume the answer sits directly overhead. Sometimes it does. Plenty of times, it...

Continue Reading
Tigerlily Takes Its Advocacy Model to Ovarian Cancer

Updated Category News Views 126

Ovarian cancer has a nasty habit of hiding behind symptoms people are taught to shrug off. Persistent bloating or pelvic pain can look like any number of ordinary problems, and that ambiguity is exactly why practical, trusted education matters. Tigerlily Foundation's new ovarian cancer initiative is not a flashy breakthrough claim. It is a grounded attempt to help women...

Continue Reading
APEC in Shenzhen Puts Trade Openness Back in Focus

Updated Category News Views 80

Shenzhen is hosting a familiar but consequential argument: prosperity gets harder to share when trade channels clog up. At the 33rd Asia-Pacific Economic Cooperation Economic Leaders' Meeting on November 18, President Xi Jinping used the opening of the APEC CEO Summit to argue for peace, openness, innovation, mutual benefit and support for the WTO-centered multilateral...

Continue Reading
Specialized Metal Makers Become the New M&A Prize Again

Updated Category News Views 14

A forgotten heat-treatment line can suddenly be worth more than a shiny new mill when buyers realize nobody can duplicate its certifications, workforce, and customer approvals overnight. That is the basic truth sitting underneath BGL's Nov. 19, 2026 assessment of the U.S. metals market. The easy headline is consolidation. The useful takeaway is much narrower: specialized...

Continue Reading
Zesty Takes Kubernetes Cost Control Into GPU Territory

Updated Category News Views 18

GPU waste has become the sort of cloud bill nobody wants to explain upstairs. A company buys scarce, expensive accelerators for AI work, then discovers that real workloads do not politely consume resources in neat, permanent blocks. Demand jumps, memory needs shift, and somebody either over-allocates to avoid trouble or under-allocates and gets ugly out-of-memory...

Continue Reading

Top 5 Most Recently Viewed Articles

Yourway Learning Raises $9 Million for Innovative AI Solutions

Updated Category News Views 261

Yourway Learning Secures $9 Million in Funding Yourway Learning has successfully closed a $9 million equity funding round, a significant boost aimed at pushing forward its mission of enhancing K-12 education through innovative AI solutions. The company's focus is on providing trusted, teacher-centered technology that addresses the unique challenges of modern educational...

Continue Reading
Investors Complain: Oddity Tech Ltd. Faces Class Action Allegations

Updated Category News Views 97

Concerns for Investors of Oddity Tech Ltd. Oddity Tech Ltd. (NASDAQ: ODD) is currently under scrutiny. Rosen Law Firm, a prominent global law firm focused on protecting investor rights, has alerted shareholders about a class action lawsuit that has been filed on their behalf. This lawsuit includes all individuals who bought Oddity's securities within a specific timeline,...

Continue Reading
Critical Update on aTyr Pharma's Securities Class Action

Updated Category News Views 219

Understanding the Class Action Lawsuit Against aTyr Pharma Investors should be aware of an ongoing securities class action lawsuit involving aTyr Pharma, Inc. (NASDAQ: ATYR), which highlights the importance of understanding legal proceedings that may impact financial interests. This lawsuit has garnered attention due to its implications for shareholders who acquired...

Continue Reading
Ping An Good Doctor's Robust Growth and Future Strategies Unveiled

Updated Category News Views 303

Ping An Good Doctor's Impressive Interim Performance Ping An Healthcare and Technology Company Limited (Stock Code: 1833.HK) has released its interim results, showcasing a remarkable performance for the first half of 2025. The company has reported total revenue reaching RMB2.5 billion, which reflects a substantial year-on-year increase of 19.5%. Moreover, the net profit...

Continue Reading
Revolutionizing Road Safety: The All-New Auto Air Pump

Updated Category News Views 171

Introducing the Auto Air Pump: A Solution for Flat Tires In an ever-evolving world where travel plays a vital role, ensuring safe and reliable journeys is of utmost importance. Few events are as frustrating as dealing with a flat tire, especially when help is far away. The Auto Air Pump has been designed to address this issue effectively. This compact yet powerful tire...

Continue Reading